Kym­ri­ah, Yescar­ta found 'cost-ef­fec­tive' in treat­ing can­cer, de­spite high price

At a time when drug pric­ing has be­come a ma­jor con­cern for the in­dus­try and the coun­try, the cost of pi­o­neer­ing new CAR-T ther­a­pies has in­spired some stick­er shock. Are these drugs worth the cost? Yes, it ap­pears so.

The non­prof­it In­sti­tute for Clin­i­cal and Eco­nom­ic Re­view (ICER) as­sessed the clin­i­cal ef­fec­tive­ness com­pared with the val­ue of leukemia ther­a­py Kym­ri­ah and lym­phoma treat­ment Yescar­ta. ICER looked at CAR-T ther­a­pies in con­trast with chemother­a­py, con­sid­er­ing pa­tient sur­vival, qual­i­ty of life, and health­care costs over the life­time of the pa­tient.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER